Please login to the form below

Not currently logged in
Email:
Password:

BIIB059

This page shows the latest BIIB059 news and features for those working in and with pharma, biotech and healthcare.

Biogen doses first patient in phase 3 systemic lupus erythematosus study

Biogen doses first patient in phase 3 systemic lupus erythematosus study

Biogen has started dosing patients in a late-stage study evaluating its potential systemic lupus erythematosus (SLE) treatment BIIB059. ... added. In addition to BIIB059, Biogen also has another investigational lupus asset – dapirolizumab pegol –

Latest news

  • Biogen scores mid-stage trial win for lupus drug BIIB059 Biogen scores mid-stage trial win for lupus drug BIIB059

    The SLE arm only tested the highest 450mg dose of BIIB059, and showed the drug reduced the number of joints with active inflammation compared to placebo at 24 weeks. ... We are excited by the LILAC study results, and the potential for BIIB059 to be a

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Understanding behaviour change: A Porterhouse Insights specialism
...
Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...